

## Administration (or supply) of VARIVAX® under Patient Group Direction

**Pharmacy Name : Pyramid Pharmacy**

Address : 413 Hoe Street, E17 9AP

### Patient details

First Name : ..... Surname : .....

Address : .....(no regular address [ ])

Post code : .....

DOB : ..... Gender : ..... NHS No : .....

Ethnicity (print separately): .....

Tel : ..... Mobile : ..... Email : .....

GP : .....

**Patient Consent : I have had a consultation with the pharmacist and consent to receive the VARIVAX®.I also have had an opportunity to ask any questions regarding the consultation.**

Signed:.....

Date : .....

### Reason for inclusion

[ ]

Patients presenting for

- Pre-exposure vaccination, or
- Post-exposure vaccination within 3 days of exposure to varicella.&nbsp;(Varivax&reg; only)

### Patient medication and comments

### Reasons for exclusions

All vaccines are contraindicated in those who have had: - A confirmed anaphylactic reaction to a previous dose of a vaccine containing the same antigens, or - A confirmed anaphylactic reaction to another component contained in the relevant vaccine, e.g. neomycin, streptomycin or polymyxin B (which may be present in trace amounts in some vaccines): check the SmPC for the individual vaccine to confirm excipients.	[ ]Yes	[ ]No
Pregnant women should be referred to their GP for advice;	[ ]Yes	[ ]No
Breastfeeding women should be referred to their GP for advice;	[ ]Yes	[ ]No
In individuals with an evolving neurological condition, immunisation should be deferred until the neurological condition has resolved or stabilised;	[ ]Yes	[ ]No
Patients with impaired immunity: the immune response could be impaired by immunosuppressive treatment or in immunodeficiency states: patients should be referred to their GP for advice;	[ ]Yes	[ ]No
Post-exposure prophylaxis;	[ ]Yes	[ ]No
Who have had a confirmed anaphylactic reaction to any varicella vaccine, or to any component of the vaccine, including gelatin, or neomycin;	[ ]Yes	[ ]No

With any blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haemic and lymphatic systems;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
Receiving immunosuppressive therapy, including high doses of corticosteroids (see below for note on low-dose immunosuppressive therapies);	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinaemia, and AIDS, or symptomatic HIV infection, or an age-specific CD4+ T-lymphocyte percentage in children between 12-35 months: CD4+ < 20%; children between 36-59 months: CD4+ < 15%;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
Individuals with a family history of congenital, or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
With active untreated tuberculosis;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
With a current illness with fever >38.5°C; however, low-grade fever itself is not a contraindication to vaccination;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
With a current illness with fever >38.5°C; however, low-grade fever itself is not a contraindication to vaccination;	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No
Patients taking salicylates	<input type="checkbox"/> ]Yes	<input type="checkbox"/> ]No

**Administration Details**

Product Name	Batch No	Expiry date (MM/YYYY)	Route of administration (Oral, Left arm, Right arm, etc)	Date & Time

**Premise:**  ]Pharmacy other via sonar authorisation .....

Name of Pharmacist :..... Signature : .....